EVMN Evommune, Inc.
Price Chart
Executive Summary
Evommune's S-1 registration has become effective, allowing for the resale of 4.49 million shares by existing shareholders. The company will not receive proceeds from this offering, which is a follow-on resale rather than a capital-raising IPO.
Actionable Insight
Monitor for initial trading volume of the resold shares, which could create short-term downward pressure. The lack of capital raise is neutral for the balance sheet, but increased float may improve liquidity for institutional investors.
Key Facts
- S-1 registration effective as of April 24, 2026
- Registration covers resale of 4.49 million shares by existing investors
- Company will not receive any proceeds from the sale
- Offering is a follow-on resale, not a primary capital-raising event
- Evommune is a clinical-stage biotech with product candidates in Phase 2 trials for inflammatory diseases
Financial Impact
No direct financial impact to Evommune — no proceeds from resale
Risk Factors
- Potential near-term share price pressure from shareholder selling post-effectiveness
- No use of proceeds for R&D or operations, limiting near-term strategic flexibility
Market Snapshot
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| EFFECT Filing (Primary) | 9999999995-26-001330 |
| Document: 9999999995-26-001330-index.html | 9999999995-26-001330 |
| Document: 9999999995-26-001330.txt | 9999999995-26-001330 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Apr 27, 2026
24d ago
|
EFFECT
| $25.00 $23.63 | ▼ −5.48% | ▼ −5.88% | $22.94 (−8.24%) |
|
Apr 21, 2026
29d ago
|
DEFA14A
| $27.12 $24.68 | ▼ −9.02% | ▼ −9.07% | $22.94 (−15.41%) |
|
Apr 17, 2026
4w ago
|
S-1
| $27.97 $25.00 | ▼ −10.62% | ▼ −11.53% | $22.94 (−17.98%) |
|
Apr 13, 2026
5w ago
|
8-K
| $26.63 $28.07 | ▲ +5.41% | ▲ +4.01% | $22.94 (−13.86%) |
|
Mar 5, 2026
10w ago
|
8-K
| $26.50 $21.99 | ▼ −17.02% | ▼ −15.49% | $22.94 (−13.43%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access